The Ebola epidemic in the Democratic Republic of the Congo has reached a sixth province as health officials track confirmed cases and deaths, according to figures reported by Yahoo Actualités. Jean Kaseya, head of the Africa CDC, announced that the northern province of Bas-Uélé has recorded its first fatality—a traveler arriving from the neighboring Haut-Uélé province, as UN News corroborates.
This fresh expansion brings the total affected provinces to six, including Bas-Uélé, Ituri, Nord-Kivu, Sud-Kivu, Haut-Uélé, and Tshopo, with the health zone of Buta marking the 54th affected zone. While total confirmed cases have reached confirmed figures with recorded deaths in updated United Nations reporting, international agencies are racing to contain regional transmission while accelerating experimental drug evaluations for the Bundibugyo strain.
Medical teams operating the international PARTNERS clinical trial have reached a milestone by enrolling 100 participants, according to the World Health Organization and Yahoo Actualités. Based at the Elikya treatment center in Bunia with support from Médecins Sans Frontières (MSF), the trial investigates the safety and efficacy of two candidate treatments: the monoclonal antibody MBP134 and the antiviral medication remdesivir.
Clinical Trial Protocol and Patient Randomization
To evaluate whether specific therapies can improve the management of patients against the Bundibugyo strain, the trial uses a randomized four-group allocation protocol. According to Dr. Olivier Kasita, a physician at the Elikya center cited by Yahoo Actualités, eligible patients who test positive are informed of the study and may choose to participate voluntarily.
Participants are assigned by chance to one of four distinct care pathways:
- Group one receives both MBP134 and remdesivir.
- Group two receives MBP134 alone.
- Group three receives remdesivir alone.
- Group four receives standard supportive care without the experimental therapeutics.
This structure ensures that three out of every four patients enrolled receive at least one experimental drug, allowing researchers to compare outcomes across cohorts. Public health officials emphasize that reaching 100 participants marks a step in the trial rather than proof of clinical efficacy, as investigators await definitive data.
Cross-Border Coordination and Regional Response
With Bas-Uélé sharing a border with the Central African Republic, the geographical shift has triggered a coordinated international defense. Mohamed Janabi, WHO regional director for Africa, traveled to Bangui to participate in a high-level meeting alongside health authorities from the Central African Republic, the Democratic Republic of the Congo, Uganda, South Sudan, and the Republic of Congo, as reported by UN News.
During the meetings in Bangui, WHO leadership stressed that robust cross-border collaboration is essential to prevent a wider regional health crisis. Officials highlighted the compounded risks of managing concurrent public health challenges, such as cholera outbreaks in neighboring areas, alongside the transmission risks along high-mobility transport corridors leading toward Uganda and South Sudan.
Epidemiological priorities outlined by the WHO focus on strengthening screening at informal border crossings, enhancing active case finding, and ensuring real-time information sharing among neighboring states. Health authorities continue monitoring transit hubs and entry points, relying on cooperative surveillance to detect potential spread before it crosses international boundaries.
Worth a look